---
id: 054
title: Tedizolid vs Linezolid Comparison
category: antimicrobials
subcategory: oxazolidinones
tags: [tedizolid, linezolid, oxazolidinones, comparison, myelosuppression]
difficulty: medium
---

## Question

How does **tedizolid** compare to linezolid in terms of dosing, efficacy, and side effects? Use the **"TEDIZOLID = BETTER Tolerated"** mnemonic.

## Answer

### **"TEDIZOLID = BETTER Tolerated" Mnemonic:**

**BETTER:**
- **B**etter tolerated (less myelosuppression)
- **E**quivalent efficacy (non-inferior)
- **T**wice the half-life (~12 hrs vs 5 hrs)
- **T**erminal dosing advantage (once daily vs BID)
- **E**xcellent safety profile (fewer GI effects)
- **R**educed drug interactions (less MAOI effect)

### **Head-to-Head Comparison:**

| Feature | Linezolid | Tedizolid | Advantage |
|---------|-----------|-----------|-----------|
| **Dosing** | 600 mg PO/IV BID | 200 mg PO/IV QD | **Tedizolid** (QD dosing) |
| **Duration (ABSSSI)** | 10 days | **6 days** | **Tedizolid** (shorter) |
| **Bioavailability** | ~100% | ~91% | Equivalent |
| **Half-life** | 5 hours | **12 hours** | **Tedizolid** |
| **Protein binding** | 31% | 70-90% | Linezolid (higher free drug) |
| **Potency (in vitro)** | Standard | **4× more potent** | **Tedizolid** |
| **Spectrum** | Gram+ (MRSA, VRE) | Gram+ (MRSA, VRE) | **Equivalent** |

### **Side Effect Profile:**

| Side Effect | Linezolid | Tedizolid | Notes |
|-------------|-----------|-----------|-------|
| **Myelosuppression** | 3-22% | **2.4%** | **Tedizolid better** |
| **Thrombocytopenia** | 3-10% | **<1%** | **Tedizolid significantly better** |
| **Nausea/vomiting** | 26.8% | **21.7%** | **Tedizolid better** |
| **GI adverse events** | 26.8% | 21.7% | Tedizolid better |
| **Serotonin syndrome risk** | Low-moderate | **Lower** | Weaker MAOI effect |
| **Optic neuropathy** | After >28 days | **Less data (rare)** | Probably lower risk |

**Clinical Trial Data (ABSSSI):**
- **Tedizolid 200mg QD × 6 days** = **Linezolid 600mg BID × 10 days** (non-inferior)
- MRSA cure rate: Tedizolid **95.2%** vs Linezolid **94%**

### **Pharmacokinetic Advantages of Tedizolid:**

**Why Less Myelosuppression?**
- Lower free drug plasma concentrations → **less mitochondrial toxicity**
- Tedizolid has lower penetration into mitochondria
- Reduced inhibition of mitochondrial protein synthesis

**Once-Daily Dosing:**
- Longer half-life (12 hrs) allows QD dosing
- Improved compliance
- Shorter total duration (6 days vs 10 days for ABSSSI)

### **Clinical Efficacy (ABSSSI):**

| Study | Tedizolid | Linezolid | Outcome |
|-------|-----------|-----------|---------|
| **ESTABLISH-1** | 200mg QD × 6d | 600mg BID × 10d | Non-inferior (79.5% vs 79.4%) |
| **ESTABLISH-2** | 200mg QD × 6d | 600mg BID × 10d | Non-inferior (85.0% vs 83.3%) |
| **MRSA subgroup** | 95.2% | 94% | Equivalent |

## Key Points

### **When to Use Tedizolid Over Linezolid:**

**Preferred in:**
1. **Prolonged therapy anticipated** (>14 days) → lower myelosuppression risk
2. **Baseline thrombocytopenia** → less bone marrow toxicity
3. **Concurrent SSRIs/SNRIs** → weaker MAOI effect
4. **Renal impairment** → no dose adjustment needed (vs linezolid accumulation)
5. **Patient compliance concerns** → once-daily dosing

### **Disadvantages of Tedizolid:**

| Factor | Issue |
|--------|-------|
| **Cost** | **Significantly more expensive** than linezolid (generic available) |
| **FDA indications** | Only ABSSSI (linezolid: ABSSSI, pneumonia, VRE bacteremia) |
| **Clinical experience** | Less data for pneumonia, VRE, osteomyelitis |
| **Off-label use** | Limited evidence for non-ABSSSI infections |

### **FDA-Approved Indications:**

**Tedizolid:**
- Acute bacterial skin and skin structure infections (ABSSSI) **only**

**Linezolid:**
- ABSSSI
- **Nosocomial pneumonia** (including MRSA)
- **VRE infections** (including bacteremia)
- Community-acquired pneumonia

### **Clinical Pearls:**
- **Tedizolid is non-inferior** to linezolid for ABSSSI
- **Shorter duration (6 days)** for tedizolid vs 10 days for linezolid
- **Cost** is major barrier to tedizolid adoption
- If prolonged therapy needed: **Tedizolid preferred** (safer)
- For pneumonia, VRE bacteremia: **Use linezolid** (more evidence)

### **Dosing:**

**Tedizolid:**
- 200 mg PO/IV QD × 6 days (ABSSSI)
- No dose adjustment for renal/hepatic impairment

**Linezolid:**
- 600 mg PO/IV BID × 10-14 days
- No dose adjustment needed (but metabolite accumulation in ESRD)

## Sources

- [Springer 2021: Pharmacokinetics and Pharmacodynamics of Tedizolid]
- [PMC11795451: Linezolid and Tedizolid Adverse Effects Review 2024]
- [PMC8300700: Tedizolid vs Linezolid PK/PD Analysis]
- [PMC6784229: Tedizolid vs Linezolid Meta-Analysis]
- [Merck Manual: Linezolid and Tedizolid]

## Media

N/A
